Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
San Diego, CA
SEC filing record 1 source field available
Fiscal year end
31 December
GYRE THERAPEUTICS, INC. has filed 1,598 SEC EDGAR filings since 16 Dec 2002

SEC filing history

Showing 751-775 of 1,000 matching filings.

Per page
25
Current page
31
4

FORM 4 SUBMISSION

Filing date
14 Jul 2017
Reporting date
13 Jul 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
14 Jul 2017
Reporting date
13 Jul 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
14 Jul 2017
Reporting date
13 Jul 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
14 Jul 2017
Reporting date
13 Jul 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
12 Jul 2017
Reporting date
11 Jul 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
12 Jul 2017
Reporting date
11 Jul 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
12 Jul 2017
Reporting date
11 Jul 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 000-51173

8-K

Filing date
16 Jun 2017
Reporting date
15 Jun 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13D/A File 005-82442

CATALYST BIOSCIENCES, INC. - AMENDMENT #6

Filing date
23 May 2017
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
DEF 14A File 000-51173

DEF 14A

Filing date
18 May 2017
Reporting date
15 Jun 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 000-51173

8-K

Filing date
11 May 2017
Reporting date
11 May 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-82442

SC 13G/A filing

Filing date
01 May 2017
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 000-51173

8-K SHARES OUTSTANDING

Filing date
24 Apr 2017
Reporting date
24 Apr 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-82442

SC 13G filing

Filing date
19 Apr 2017
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-82442

SC 13G filing

Filing date
13 Apr 2017
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 000-51173

FORM 8-K

Filing date
13 Apr 2017
Reporting date
07 Apr 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
424B4 File 333-216663

424B4

Filing date
10 Apr 2017
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-216663

EFFECT filing

Filing date
06 Apr 2017
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
S-1MEF File 333-217186

S-1MEF

Filing date
06 Apr 2017
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
CORRESP

CORRESP filing

Filing date
06 Apr 2017
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
CORRESP

CORRESP filing

Filing date
06 Apr 2017
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
S-1/A File 333-216663

S-1/A

Filing date
05 Apr 2017
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
S-1/A File 333-216663

FORM S-1/A

Filing date
04 Apr 2017
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
FWP File 333-216663

FWP

Filing date
03 Apr 2017
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .